US Stock Futures Rise; GDP, Jobless Claims Data In Focus

Loading...
Loading...
Pre-open movers
US stock futures gained in early pre-market trading, ahead of economic data. Data on GDP growth for the fourth quarter and weekly jobless claims will be released at 8:30 a.m. ET. The pending home sales index for February will be released at 10:00 a.m. ET, while the Kansas City Fed manufacturing index for March will be released at 11:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 39 points to 16,218.00, while the Standard & Poor's 500 index futures rose 4.90 points to 1,847.50. Futures for the Nasdaq 100 index gained 9 points to 3,581.75.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.26%, London's FTSE 100 index dropping 0.42% and STOXX Europe 600 Index jumping 0.08%. German DAX 30 index climbed 0.06% and French CAC 40 Index fell 0.06%. French consumer confidence index climbed to 88 in March versus 85 in February. Italy's manufacturing business confidence index surged to 99.2 in March, versus 99.1 in February. UK retail sales rose 1.7% on the month in February. Asian markets ended mixed today. Japan's Nikkei Stock Average rose 1.01%, Hong Kong's Hang Seng Index declined 0.24% and China's Shanghai Composite Index fell 0.83% and India's BSE Sensex climbed 0.42%.
Broker Recommendation
Analysts at Keefe Bruyette & Woods downgraded Citigroup
C
from “outperform” to “market perform.” The target price for Citigroup has been lowered from $58 to $52. Citigroup's shares dropped 4.80% to $47.75 in pre-market trading.
Breaking news
  • Spherix SPEX today announced that it has commenced patent litigation in the United States District Court for the District of Delaware against Cisco CSCO alleging that the San Jose, CA based company infringes 11 patents owned by Spherix. To read the full news, click here.
  • Sanofi SNY and Regeneron Pharmaceuticals REGN today announced that data from alirocumab clinical studies will be presented at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, D.C. March 29-31. To read the full news, click here.
  • Clovis Oncology CLVS announced today updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686, the Company's novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. To read the full news, click here.
  • The Federal Reserve on Wednesday announced it has approved the capital plans of 25 bank holding companies participating in the Comprehensive Capital Analysis and Review (CCAR). To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsKeefe Bruyette & WoodsUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...